Enhertu-Induced Resistant Tumor Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies. However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models. WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused on ADC therapeutics against breast and lung cancer.
Learn about our comprehensive platform of ADC services by clicking HERE
Enhertu-induced resistant tumor models
Related Content
Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...
VIEW RESOURCEAntibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...
VIEW RESOURCE